CN104788482A - A method of preparing 2-aminopyrimidine-5-boronic acid pinacol ester - Google Patents

A method of preparing 2-aminopyrimidine-5-boronic acid pinacol ester Download PDF

Info

Publication number
CN104788482A
CN104788482A CN201510032746.5A CN201510032746A CN104788482A CN 104788482 A CN104788482 A CN 104788482A CN 201510032746 A CN201510032746 A CN 201510032746A CN 104788482 A CN104788482 A CN 104788482A
Authority
CN
China
Prior art keywords
pinacol ester
acid pinacol
boronic acid
aminopyrimidine
chloropyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201510032746.5A
Other languages
Chinese (zh)
Other versions
CN104788482B (en
Inventor
冷延国
桂迁
张进
余锦华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Weizhi Fine Chemical Co ltd
Original Assignee
CANGZHOU PURUI ORIENT TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CANGZHOU PURUI ORIENT TECHNOLOGY Co Ltd filed Critical CANGZHOU PURUI ORIENT TECHNOLOGY Co Ltd
Priority to CN201510032746.5A priority Critical patent/CN104788482B/en
Publication of CN104788482A publication Critical patent/CN104788482A/en
Application granted granted Critical
Publication of CN104788482B publication Critical patent/CN104788482B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种制备2-氨基嘧啶-5-硼酸频那醇酯的方法,从原料2-氯嘧啶出发,在BF3-Et2O催化下,与NBS发生溴代得到2-氯-5-溴嘧啶;随后该中间体与n-Bu3MgLi在-20~-10℃反应,随后加入甲氧基硼酸频那醇酯或异丙氧基硼酸频那醇酯进行硼化后得到2-氯嘧啶-5-硼酸频那醇酯;接着加入氨水中或氨甲醇溶液,80~100℃密封反应后得到2-氨基嘧啶-5-硼酸频那醇酯。本发明合成工艺条件温和,避免了超低温反应,而且反应可以连续进行,只需在最终产物时进行简单重结晶即可得到纯品。The invention discloses a method for preparing 2-aminopyrimidine-5-boronic acid pinacol ester. Starting from the raw material 2-chloropyrimidine, under the catalysis of BF 3 -Et 2 O, bromination occurs with NBS to obtain 2-chloro- 5-bromopyrimidine; then react this intermediate with n-Bu 3 MgLi at -20~-10°C, and then add methoxyboronic acid pinacol ester or isopropoxyboronic acid pinacol ester to obtain 2 -Chloropyrimidine-5-boronic acid pinacol ester; then add ammonia water or ammonia methanol solution, seal reaction at 80-100°C to obtain 2-aminopyrimidine-5-boronic acid pinacol ester. The synthesis process of the invention has mild conditions, avoids ultra-low temperature reaction, and the reaction can be carried out continuously, and the pure product can be obtained only by simple recrystallization in the final product.

Description

一种制备2-氨基嘧啶-5-硼酸频那醇酯的方法A method for preparing 2-aminopyrimidine-5-boronic acid pinacol ester

技术领域 technical field

本发明涉及一种制备2-氨基嘧啶-5-硼酸频那醇酯的方法,属于药物中间体合成领域。 The invention relates to a method for preparing 2-aminopyrimidine-5-boronic acid pinacol ester, which belongs to the field of synthesis of pharmaceutical intermediates.

技术背景 technical background

在已知的上市或在研新药中I型PI3K抑制剂Apitolisib和激酶抑制剂Votrient,都含有2-氨基嘧啶基团,并且有更多的研究仍将此片断作为重要的结构单元。2-氨基嘧啶-5-硼酸频那醇酯作为其中一个关键中间体,目前已有公开资料的合成方法:主要包括1)采用2-氨基-5-碘嘧啶与频那醇硼烷在Pd(PPh)4催化下(参考:Org.Biomol.Chem.,2011,9,3139)或2-氨基-5-溴嘧啶与联硼酸频那醇酯在PdCl2dppf存在下偶联(参考:WO 2012/109423 A1);2)采用同样的原料将氨基用Boc(参考:CN102399235A和CN102367260A)或二苯亚甲基(参考:US 2008/0269523 A1)保护后,(或是不保护直接,参考:Eur.J.Org.Chem.2007,5712)采用丁基锂/硼酸三异丙酯/-78℃下超低温反应先形成硼酸,随后脱保护后,再接着与频那醇反应成酯。 The type I PI3K inhibitor Apitolisib and the kinase inhibitor Votrient, known to be on the market or under research, both contain a 2-aminopyrimidine group, and more studies still regard this fragment as an important structural unit. As one of the key intermediates, 2-aminopyrimidine-5-boronic acid pinacol ester has a synthetic method with public information: mainly including 1) using 2-amino-5-iodopyrimidine and pinacol borane in Pd( PPh) catalyzed by (reference: Org.Biomol.Chem., 2011, 9, 3139) or 2-amino-5-bromopyrimidine and biboronic acid pinacol ester coupling in the presence of PdCl 2 dppf (reference: WO 2012 /109423 A1); 2) After using the same raw material to protect the amino group with Boc (reference: CN102399235A and CN102367260A) or diphenylmethylene (reference: US 2008/0269523 A1), (or directly without protection, reference: Eur .J.Org.Chem.2007, 5712) using butyllithium/triisopropyl borate/ultra-low temperature reaction at -78°C to form boric acid first, then after deprotection, then react with pinacol to form ester.

上述方法:1)偶联催化剂用量较大,成本高,而且产物有重金属残留;2)氨基采用二苯甲酮保护时,按照专利方法第一步得不到缩合产物,采用Boc保护时需要用将氮全部保护起来;氨基不保护直接反应的方法收率不稳定,重现性差,且该类方法都存在需要超低温反应的缺点。 The above method: 1) the amount of coupling catalyst is large, the cost is high, and the product has heavy metal residues; 2) when the amino group is protected by benzophenone, the condensation product cannot be obtained according to the first step of the patent method, and Boc protection needs to be used. The nitrogen is completely protected; the yield of the direct reaction method without protection of the amino group is unstable and the reproducibility is poor, and all such methods have the disadvantage of requiring ultra-low temperature reaction.

发明内容 Contents of the invention

本发明所要解决的技术问题是提供一种新的制备2-氨基嘧啶-5-硼酸频那醇酯的方法,包括以下步骤: The technical problem to be solved by this invention is to provide a new method for preparing 2-aminopyrimidine-5-boronic acid pinacol ester, comprising the following steps:

第一步,在BF3-Et2O催化作用下,2-氯嘧啶与NBS在乙腈或乙二醇二甲醚溶剂中回流反应,得到2-氯-5-溴嘧啶; In the first step, under the catalysis of BF 3 -Et 2 O, 2-chloropyrimidine and NBS are refluxed in acetonitrile or ethylene glycol dimethyl ether solvent to obtain 2-chloro-5-bromopyrimidine;

第二步,保持温度在-20~-10℃将2.5M n-BuLi加入到n-BuMgBr中,制备成n-Bu3MgLi,随后维持该温度将第一步得到的2-氯-5-溴嘧啶溶于四氢呋喃中滴入上述溶液中,保温1小时,滴加甲氧基硼酸频那醇酯或异丙氧基硼酸频那醇酯,保温1小时,溶液升到室温,搅拌过夜,加饱和氯化铵淬灭,用乙酸乙酯萃取, 蒸干得到2-氯嘧啶-5-硼酸频那醇酯; In the second step, 2.5M n-BuLi was added to n-BuMgBr by keeping the temperature at -20~-10°C to prepare n-Bu 3 MgLi, and then the 2-chloro-5- Bromopyrimidine was dissolved in tetrahydrofuran and dropped into the above solution, kept warm for 1 hour, added dropwise methoxy pinacol borate or isopropoxy borate pinacol ester, kept warm for 1 hour, the solution rose to room temperature, stirred overnight, added Saturated ammonium chloride quenched, extracted with ethyl acetate, and evaporated to dryness to obtain 2-chloropyrimidine-5-boronic acid pinacol ester;

第三步,在压力釜内,将第二步得到的2-氯嘧啶-5-硼酸频那醇酯加入氨水或氨甲醇中,80~100℃反应6小时,溶液旋干后加入四氢呋喃或乙酸乙酯溶解后过滤,再次蒸干溶剂后加甲醇重结晶得到2-氨基嘧啶-5-硼酸频那醇酯。 The third step is to add the 2-chloropyrimidine-5-boronic acid pinacol ester obtained in the second step into ammonia water or ammonia methanol in the autoclave, and react at 80-100°C for 6 hours, spin the solution to dry and add tetrahydrofuran or acetic acid The ethyl ester was dissolved and filtered, and the solvent was evaporated to dryness again, and methanol was added to recrystallize to obtain 2-aminopyrimidine-5-boronic acid pinacol ester.

进一步地,所述第一步中,2-氯嘧啶与NBS、BF3-Et2O的摩尔比为1∶1-1.5∶0.05-0.3。 Further, in the first step, the molar ratio of 2-chloropyrimidine to NBS and BF 3 -Et 2 O is 1:1-1.5:0.05-0.3.

进一步地,所述第二步中,n-BuLi与n-BuMgBr的摩尔比为2∶1;2-氯-5-溴嘧啶与n-Bu3MgLi、甲氧基硼酸频那醇酯或异丙氧基硼酸频那醇酯的摩尔比为1∶0.4-0.5∶1.1-1.5。 Further, in the second step, the molar ratio of n-BuLi to n-BuMgBr is 2:1 ; The molar ratio of propoxy borate pinacol ester is 1:0.4-0.5:1.1-1.5.

进一步地,所述第三步中,2-氯嘧啶-5-硼酸频那醇酯与氨水或氨甲醇摩尔用量比1∶2-5。 Further, in the third step, the molar ratio of 2-chloropyrimidine-5-boronic acid pinacol ester to ammonia water or ammonia methanol is 1:2-5.

反应式如下:  The reaction formula is as follows:

发明有益效果  Beneficial effects of the invention

本发明合成工艺条件温和,避免了超低温反应,而且反应可以连续进行,只需在最终产物时进行简单重结晶即可得到纯品。 The synthesis process of the invention has mild conditions, avoids ultra-low temperature reaction, and the reaction can be carried out continuously, and the pure product can be obtained only by simple recrystallization in the final product.

具体实施方式 Detailed ways

实施例1 Example 1

一种制备2-氨基嘧啶-5-硼酸频那醇酯的方法,包括以下步骤: A method for preparing 2-aminopyrimidine-5-boronic acid pinacol ester, comprising the following steps:

在反应瓶内加入2-氯嘧啶11.5g(0.1mol)、溴化试剂NBS 21.3g(0.12mol)和乙腈80mL,室温下加入催化量BF3-Et2O 2.8g(0.02mol),加入完毕后,升温至回流反应5-8小时,TLC检测反应完毕后,降温,过滤掉不溶固体后,减压蒸馏溶剂后,加入乙酸乙酯溶解,再滴加入45mL饱和Na2CO3溶液洗涤,分出有机层,水层再加入60mL乙酸乙酯,再次分层后,合并有机层后,饱和食盐水洗涤,旋 干得到浅黄色2-氯-5-溴嘧啶固体14.1g,直接用于下步反应中。1H-NMR(400MHz,CDCl3):8.70(s,2H)。 Add 11.5g (0.1mol) of 2-chloropyrimidine, 21.3g (0.12mol) of brominating reagent NBS and 80mL of acetonitrile into the reaction flask, add catalytic amount of BF 3 -Et 2 O 2.8g (0.02mol) at room temperature, and complete the addition After that, the temperature was raised to reflux for 5-8 hours. After the reaction was detected by TLC, the temperature was lowered, and the insoluble solid was filtered off. After the solvent was distilled under reduced pressure, ethyl acetate was added to dissolve, and then 45 mL of saturated Na2CO3 solution was added dropwise to wash, and the The organic layer was taken out, and 60 mL of ethyl acetate was added to the aqueous layer. After layering again, the organic layers were combined, washed with saturated brine, and spin-dried to obtain 14.1 g of light yellow 2-chloro-5-bromopyrimidine solid, which was directly used in the next step. Reacting. 1 H-NMR (400 MHz, CDCl3): 8.70 (s, 2H).

氮气保护下,在反应瓶内加入29.2mL事先制备好的n-BuMgBr溶液(1M四氢呋喃溶液)冷却至-20℃,随后维持内温在-20~-10℃滴加23.4mL n-BuLi(2.5M己烷溶液),滴加完毕保温搅拌30分钟后,将第一步得到的2-氯-5-溴嘧啶14.1g(73mmol)和无水四氢呋喃40mL,滴毕保温1小时,TLC检测交换完全,随后维持该温度滴加甲氧基硼酸频那醇酯13.3g(84mmol)的无水四氢呋喃溶液,保温1小时,溶液自然升至室温,搅拌过夜,加饱和氯化铵淬灭调PH为4-5,乙酸乙酯70mL萃取,合并有机层蒸干得到2-氯嘧啶-5-硼酸频那醇酯固体粗品12.1g,GC含量大于95%,收率69%,可以直接进入下一步反应中;1H-NMR(400MHz,CDCl3):8.60(s,2H),1.29(s,12H)。 Under the protection of nitrogen, add 29.2mL n-BuMgBr solution (1M tetrahydrofuran solution) prepared in advance to the reaction flask and cool to -20°C, then maintain the internal temperature at -20~-10°C and add 23.4mL n-BuLi (2.5 M hexane solution), after the dropwise addition was completed and incubated and stirred for 30 minutes, the 2-chloro-5-bromopyrimidine 14.1g (73mmol) and anhydrous tetrahydrofuran 40mL obtained in the first step were incubated for 1 hour after the dropwise addition, and TLC detected that the exchange was complete , then maintain this temperature dropwise anhydrous tetrahydrofuran solution of methoxy borate pinacol ester 13.3g (84mmol), keep warm for 1 hour, the solution naturally rises to room temperature, stir overnight, add saturated ammonium chloride to quench and adjust the pH to be 4 -5, extracted with 70 mL of ethyl acetate, combined the organic layers and evaporated to dryness to obtain 12.1 g of solid crude product of 2-chloropyrimidine-5-boronic acid pinacol ester, the GC content was greater than 95%, and the yield was 69%, which could be directly used in the next reaction ; 1 H-NMR (400 MHz, CDCl3): 8.60 (s, 2H), 1.29 (s, 12H).

在100mL压力釜内,将第二步得到的2-氯嘧啶-5-硼酸频那醇酯12.1g(50mmol)加入22.5g 28%氨水(180mmol)中,100℃密封反应6小时,溶液旋干后加入150mL乙酸乙酯溶解后过滤,再次蒸干溶剂后加甲醇重结晶得到白色晶状固体2-氨基嘧啶-5-硼酸频那醇酯8.6g,收率78%。1H-NMR(400MHz,CDCl3):8.58(s,2H),5.80(s,2H),1.32(s,12H); In a 100mL autoclave, 12.1g (50mmol) of 2-chloropyrimidine-5-boronic acid pinacol ester obtained in the second step was added to 22.5g 28% ammonia water (180mmol), and the reaction was sealed at 100°C for 6 hours, and the solution was spin-dried Then add 150mL of ethyl acetate to dissolve and filter, evaporate the solvent again and add methanol to recrystallize to obtain 8.6g of white crystalline solid 2-aminopyrimidine-5-boronic acid pinacol ester with a yield of 78%. 1 H-NMR (400MHz, CDCl3): 8.58(s, 2H), 5.80(s, 2H), 1.32(s, 12H);

实施例2 Example 2

一种制备2-氨基嘧啶-5-硼酸频那醇酯的方法,包括以下步骤: A method for preparing 2-aminopyrimidine-5-boronic acid pinacol ester, comprising the following steps:

在反应瓶内加入2-氯嘧啶11.5g(0.1mol)、溴化试剂NBS 21.3g(0.12mol)和乙二醇二甲醚80mL,室温下加入催化量BF3-Et2O 4.2g(0.03mol),加入完毕后,升温至回流反应5-8小时,TLC检测反应完毕后,降温,过滤掉不溶固体后,减压蒸馏溶剂后,加入乙酸乙酯溶解,再滴加入45mL饱和Na2CO3溶液洗涤,分出有机层,水层再加入60mL乙酸乙酯,再次分层后,合并有机层后,饱和食盐水洗涤,旋干得到浅黄色2-氯-5-溴嘧啶固体13.2g,直接用于下步反应中。 1H-NMR(400MHz,CDCl3):8.70(s,2H)。 Add 11.5g (0.1mol) of 2-chloropyrimidine, 21.3g (0.12mol) of brominating reagent NBS and 80mL of ethylene glycol dimethyl ether into the reaction flask, and add catalytic amount of BF 3 -Et 2 O 4.2g (0.03 mol), after the addition was completed, the temperature was raised to reflux for 5-8 hours. After the reaction was detected by TLC, the temperature was lowered, and the insoluble solid was filtered off. After the solvent was distilled under reduced pressure, ethyl acetate was added to dissolve, and then 45 mL of saturated Na 2 CO was added dropwise. 3. The solution was washed, the organic layer was separated, and 60 mL of ethyl acetate was added to the aqueous layer. After layering again, the organic layers were combined, washed with saturated saline, and spin-dried to obtain 13.2 g of light yellow 2-chloro-5-bromopyrimidine solid. used directly in the next reaction. 1 H-NMR (400 MHz, CDCl3): 8.70 (s, 2H).

氮气保护下,氮气保护下,在反应瓶内加入29.2mL事先制备好的n-BuMgBr溶液(1M四氢呋喃溶液)冷却至-20℃,随后维持内温在-20~-10℃滴加23.4mL n-BuLi(2.5M己烷溶液),滴加完毕保温搅拌30分钟后,将第一步得到的2-氯-5-溴嘧啶14.1g(73mmol)和无水四氢呋喃40mL,滴毕保温1小时,TLC检测交换 完全,随后维持该温度滴加异丙氧基硼酸频那醇酯15.6g(84mmol)的无水四氢呋喃溶液,保温1小时,溶液自然升至室温,搅拌过夜,加饱和氯化铵淬灭调PH为4-5,乙酸乙酯80mL萃取,合并有机层蒸干得到2-氯嘧啶-5-硼酸频那醇酯固体粗品10.5g,GC含量大于96%,收率64%,可以直接进入下一步反应中;1H-NMR(400MHz,CDCl3):8.60(s,2H),1.29(s,12H)。 Under the protection of nitrogen, under the protection of nitrogen, add 29.2mL of n-BuMgBr solution (1M tetrahydrofuran solution) prepared in advance to the reaction bottle and cool it to -20°C, then maintain the internal temperature at -20~-10°C and add 23.4mL n-BuMgBr dropwise -BuLi (2.5M hexane solution), after the dropwise addition was completed and incubated and stirred for 30 minutes, 14.1g (73mmol) of 2-chloro-5-bromopyrimidine obtained in the first step and 40mL of anhydrous tetrahydrofuran were incubated for 1 hour after the dropwise addition. TLC detects that the exchange is complete, then maintains the temperature and drips anhydrous tetrahydrofuran solution of 15.6 g (84 mmol) of isopropoxy pinacol borate ester, and keeps warm for 1 hour. The solution naturally rises to room temperature, stirs overnight, and quenches with saturated ammonium chloride. The pH was adjusted to 4-5, extracted with 80 mL of ethyl acetate, and the combined organic layers were evaporated to dryness to obtain 10.5 g of solid crude product of 2-chloropyrimidine-5-boronic acid pinacol ester, the GC content was greater than 96%, and the yield was 64%, which could be directly Into the next reaction; 1 H-NMR (400MHz, CDCl3): 8.60 (s, 2H), 1.29 (s, 12H).

在100mL压力釜内,将第二步得到的2-氯嘧啶-5-硼酸频那醇酯7.2g(30mmol)加入9.42mL 7M氨甲醇溶液(66mmol)中,80℃密封反应8小时,溶液旋干后加入100mL四氢呋喃溶解后过滤,再次蒸干溶剂后加甲醇重结晶得到白色晶状固体2-氨基嘧啶-5-硼酸频那醇酯4.4g,收率66%。1H-NMR(400MHz,CDCl3):8.58(s,2H),5.80(s,2H),1.32(s,12H)。 In a 100mL autoclave, 7.2g (30mmol) of 2-chloropyrimidine-5-boronic acid pinacol ester obtained in the second step was added to 9.42mL 7M ammonia methanol solution (66mmol), and the reaction was sealed at 80°C for 8 hours, and the solution was spun After drying, add 100mL tetrahydrofuran to dissolve, filter, evaporate the solvent again, and add methanol to recrystallize to obtain 4.4g of white crystalline solid 2-aminopyrimidine-5-boronic acid pinacol ester, with a yield of 66%. 1 H-NMR (400 MHz, CDCl3): 8.58 (s, 2H), 5.80 (s, 2H), 1.32 (s, 12H).

Claims (4)

1.一种制备2-氨基嘧啶-5-硼酸频那醇酯的方法,其特征在于包括以下步骤:1. a method for preparing 2-aminopyrimidine-5-boronic acid pinacol ester, is characterized in that comprising the following steps: 第一步,在BF3-Et2O催化作用下,2-氯嘧啶与NBS在乙腈或乙二醇二甲醚溶剂中回流反应,得到2-氯-5-溴嘧啶;In the first step, under the catalysis of BF 3 -Et 2 O, 2-chloropyrimidine and NBS are refluxed in acetonitrile or ethylene glycol dimethyl ether solvent to obtain 2-chloro-5-bromopyrimidine; 第二步,保持温度在-20~-10℃将2.5M n-BuLi加入到n-BuMgBr中,制备成n-Bu3MgLi,随后维持该温度将第一步得到的2-氯-5-溴嘧啶溶于四氢呋喃中滴入上述溶液中,保温1小时,滴加甲氧基硼酸频那醇酯或异丙氧基硼酸频那醇酯,保温1小时,溶液升到室温,搅拌过夜,加饱和氯化铵淬灭,用乙酸乙酯萃取,蒸干得到2-氯嘧啶-5-硼酸频那醇酯;In the second step, 2.5M n-BuLi was added to n-BuMgBr by keeping the temperature at -20~-10°C to prepare n-Bu 3 MgLi, and then the 2-chloro-5- Bromopyrimidine was dissolved in tetrahydrofuran and dropped into the above solution, kept warm for 1 hour, added dropwise methoxy pinacol borate or isopropoxy borate pinacol ester, kept warm for 1 hour, the solution rose to room temperature, stirred overnight, added Saturated ammonium chloride quenched, extracted with ethyl acetate, and evaporated to dryness to obtain 2-chloropyrimidine-5-boronic acid pinacol ester; 第三步,在压力釜内,将第二步得到的2-氯嘧啶-5-硼酸频那醇酯加入氨水中或氨甲醇溶液中,80~100℃反应6小时,溶液旋干后加入四氢呋喃或乙酸乙酯溶解后过滤,再次蒸干溶剂后加甲醇重结晶得到2-氨基嘧啶-5-硼酸频那醇酯。The third step is to add the 2-chloropyrimidine-5-boronic acid pinacol ester obtained in the second step into ammonia water or ammonia methanol solution in the autoclave, and react at 80-100°C for 6 hours. After the solution is spin-dried, add tetrahydrofuran Or dissolve in ethyl acetate and filter, evaporate the solvent again and add methanol for recrystallization to obtain 2-aminopyrimidine-5-boronic acid pinacol ester. 2.根据权利要求1所述一种制备2-氨基嘧啶-5-硼酸频那醇酯的方法,其特征在于:所述第一步中,2-氯嘧啶与NBS、BF3-Et2O的摩尔比为1∶1-1.5∶0.05-0.3。2. A method for preparing 2-aminopyrimidine-5-boronic acid pinacol ester according to claim 1, characterized in that: in the first step, 2-chloropyrimidine and NBS, BF 3 -Et 2 O The molar ratio is 1:1-1.5:0.05-0.3. 3.根据权利要求1所述一种制备2-氨基嘧啶-5-硼酸频那醇酯的方法,其特征在于:所述第二步中,所述n-BuLi与n-BuMgBr的摩尔比为2∶1;所述2-氯-5-溴嘧啶与n-Bu3MgLi、甲氧基硼酸频那醇酯或异丙氧基硼酸频那醇酯的摩尔比为1∶0.4-0.5∶1.1-1.5。3. a kind of method for preparing 2-aminopyrimidine-5-boronic acid pinacol ester according to claim 1, is characterized in that: in the described second step, the mol ratio of described n-BuLi and n-BuMgBr is 2:1; the molar ratio of 2-chloro-5-bromopyrimidine to n-Bu 3 MgLi, pinacol methoxy borate or pinacol isopropoxy borate is 1:0.4-0.5:1.1 -1.5. 4.根据权利要求1所述一种制备2-氨基嘧啶-5-硼酸频那醇酯的方法,其特征在于:所述第三步中,2-氯嘧啶-5-硼酸频那醇酯与氨水或氨甲醇摩尔用量比1∶2-5。4. a kind of method for preparing 2-aminopyrimidine-5-boric acid pinacol ester according to claim 1, is characterized in that: in the described 3rd step, 2-chloropyrimidine-5-boric acid pinacol ester and The molar ratio of ammonia water or ammonia to methanol is 1:2-5.
CN201510032746.5A 2015-01-23 2015-01-23 A method for preparing 2-aminopyrimidine-5-boronic acid pinacol ester Expired - Fee Related CN104788482B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510032746.5A CN104788482B (en) 2015-01-23 2015-01-23 A method for preparing 2-aminopyrimidine-5-boronic acid pinacol ester

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510032746.5A CN104788482B (en) 2015-01-23 2015-01-23 A method for preparing 2-aminopyrimidine-5-boronic acid pinacol ester

Publications (2)

Publication Number Publication Date
CN104788482A true CN104788482A (en) 2015-07-22
CN104788482B CN104788482B (en) 2016-09-14

Family

ID=53553714

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510032746.5A Expired - Fee Related CN104788482B (en) 2015-01-23 2015-01-23 A method for preparing 2-aminopyrimidine-5-boronic acid pinacol ester

Country Status (1)

Country Link
CN (1) CN104788482B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113861230A (en) * 2021-11-02 2021-12-31 河南应用技术职业学院 Synthetic method of terbinafine intermediate
CN119019440A (en) * 2024-10-24 2024-11-26 浙江雅辰药物科技股份有限公司 A preparation method of 6-cyclopropylpyridine-3-boric acid pinacol ester

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101910150A (en) * 2007-11-05 2010-12-08 诺瓦提斯公司 4-benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
CN101993419A (en) * 2009-08-20 2011-03-30 浙江九洲药业股份有限公司 Preparation method of 4-[(5-bromo-4,6-dichloro-2-pyrimidinyl)amino] cyanobenzene
CN102381944A (en) * 2011-08-29 2012-03-21 南京大学 Method for synthesizing C-13 and C-14 labelled bisphenol A and C-13 and C-14 labelled tetrabromobisphenol A
CN103288746A (en) * 2013-05-17 2013-09-11 安徽世华化工有限公司 Preparation method of 2-azyl-5-bromopyrimidine
WO2014090147A1 (en) * 2012-12-14 2014-06-19 上海恒瑞医药有限公司 Pyrimidine derivatives and salts thereof, preparation method and pharmaceutical use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101910150A (en) * 2007-11-05 2010-12-08 诺瓦提斯公司 4-benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
CN101993419A (en) * 2009-08-20 2011-03-30 浙江九洲药业股份有限公司 Preparation method of 4-[(5-bromo-4,6-dichloro-2-pyrimidinyl)amino] cyanobenzene
CN102381944A (en) * 2011-08-29 2012-03-21 南京大学 Method for synthesizing C-13 and C-14 labelled bisphenol A and C-13 and C-14 labelled tetrabromobisphenol A
WO2014090147A1 (en) * 2012-12-14 2014-06-19 上海恒瑞医药有限公司 Pyrimidine derivatives and salts thereof, preparation method and pharmaceutical use thereof
CN103288746A (en) * 2013-05-17 2013-09-11 安徽世华化工有限公司 Preparation method of 2-azyl-5-bromopyrimidine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
K. FANDRICK ET AL.: "Development of an Asymmetric Synthesis of a Chiral Quaternary FLAP Inhibitor", 《J. ORG. CHEM》 *
P J JI ET AL.: "The Kinetics and Mechanisms of Aromatic Nucleophilic Substitution Reactions in Liquid Ammonia", 《J. ORG. CHEM》 *
王红学等: "新(4"-三氟甲基嘧啶基)-2-苯磺酰脲衍生物的合成机生物活性", 《高等学校化学学报》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113861230A (en) * 2021-11-02 2021-12-31 河南应用技术职业学院 Synthetic method of terbinafine intermediate
CN113861230B (en) * 2021-11-02 2024-08-16 河南应用技术职业学院 Synthetic method of terbanserin intermediate
CN119019440A (en) * 2024-10-24 2024-11-26 浙江雅辰药物科技股份有限公司 A preparation method of 6-cyclopropylpyridine-3-boric acid pinacol ester

Also Published As

Publication number Publication date
CN104788482B (en) 2016-09-14

Similar Documents

Publication Publication Date Title
CN1966482B (en) Preparation method of a class of cyclohexyl-containing lateral ortho-difluorobenzene liquid crystal compounds
CN107936029B (en) Method for synthesizing Ribociclib
CN102827087B (en) Synthetic method of erlotinib
CN104788482B (en) A method for preparing 2-aminopyrimidine-5-boronic acid pinacol ester
CN106674264A (en) Synthetic method for (2,2,2-trifluoroethoxyl) phenylboronic acid compounds
CN101671352A (en) Method for preparing fluoride-bearing phenyloboric acid
CN103044468B (en) Preparation method of N-(2-pyrazine carbonyl)-L-phenylalanine-L- leucine boracic acid
CN108129513A (en) A kind of method for synthesizing Bouguer and replacing Buddhist nun's intermediate
CN104311485A (en) Preparation method of medicine bosutinib for treating leukemia
CN103012268B (en) Novel preparation method for ivabradine
CN108752184B (en) Preparation method of SGLT2 inhibitor intermediate
CN100509729C (en) Method for synthesizing resveratrol
CN114907204A (en) Synthesis method of piparidic acid
CN105237486B (en) The synthetic method of the dimethyl pyrazine of 2 ethyl 3,6
CN1962624A (en) Method for synthesis of rivastigmine
CN106397470B (en) A kind of synthetic method of the fluorenes of 3,3 ' hypoboric acid pinacol ester, 9,9 ' spiral shell two
CN101397247B (en) Indan-1-carboxylic acid synthesis method of bulk drug for clidanic acid
CN101723879B (en) Method for synthesizing (R)-3-ethyl piperidine hydrochloride
CN101265201B (en) A kind of synthetic method of tramadol hydrochloride
CN103242244B (en) Canertinib preparation method
CN102516284B (en) Silole substituted compound containing terpyridine and preparation method and application thereof
CN104387259A (en) Method for preparing 2,4,5-trifluorophenylacetic acid
CN102702192A (en) Synthesis method of vinpocetine
CN102603615B (en) Intermediates of 2-acetonyl-3-methoxy piperidine and preparation method of 2-acetonyl-3-methoxy piperidine
CN113512031B (en) Preparation method of LSD1 enzyme inhibitor TAK-418 intermediate compound

Legal Events

Date Code Title Description
DD01 Delivery of document by public notice

Addressee: CANGZHOU PURUI DONGFANG SCIENCE & TECHNOLOGY Co.,Ltd.

Document name: Notification of Passing Preliminary Examination of the Application for Invention

C06 Publication
PB01 Publication
DD01 Delivery of document by public notice

Addressee: Leng Yanguo

Document name: Notification of Passing Examination on Formalities

EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20180517

Address after: 301914 No. 4, Cuiping Road, economic development zone, Ji Zhou District, Tianjin

Patentee after: TIANJIN WEIZHI FINE CHEMICAL CO.,LTD.

Address before: 061108 Western District of Lingang Economic and Technological Development Zone, Huanghua, Cangzhou, Hebei

Patentee before: CANGZHOU PURUI DONGFANG SCIENCE & TECHNOLOGY Co.,Ltd.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160914

CF01 Termination of patent right due to non-payment of annual fee